E-ISSN: 2667-6370
Effect of Smoking on Reversing Neuromuscular Block
PDF
Cite
Share
Request
Original Article
VOLUME: 44 ISSUE: 4
P: 206-211
August 2016

Effect of Smoking on Reversing Neuromuscular Block

Turk J Anaesthesiol Reanim 2016;44(4):206-211
DOI: 10.5152/TJAR.2016.97720
Ömür Öztürk 1
Gülbin Yalçın Sezen 2
Handan Ankaralı 3
Onur Özlü 2
Yavuz Demiraran 2
Hakan Ateş 2
Burhan Dost 2
1. Department of Anaesthesiology and Reanimation, Kafkas University School of Medicine, Kars, Turkey
2. Department of Anaesthesiology and Reanimation, Düzce University School of Medicine, Düzce, Turkey
3. Department of Biostatistics, Düzce University School of Medicine, Düzce, Turkey
No information available.
No information available
Received Date: 03.03.2016
Accepted Date: 17.05.2016
PDF
Cite
Share
Request

ABSTRACT

Objective:

Rocuronium is a non-depolarising, intermediate-acting, monoquaternary amino steroid and was brought into clinical use as a potentially ideal muscle relaxant. Post-operative residual curarisation (PORC) results from the prolonged effects of non-depolarising neuromuscular blocking agents. This is a common problem and seriously affects patient safety. No recent study has investigated the effects of sugammadex on smokers, which is often used to restore neuromuscular block and avoid PORC. This study compares the severity of the effects of sugammadex used for antagonising rocuronium bromide and antagonism durations in smokers and non-smokers.

Methods:

This randomised, prospective study included 40 patients scheduled for elective surgery and belonging to classes I and II based the American Society of Anesthesiologists classification, who were either smokers for at least 10 years or non-smokers. Patients underwent routine and neuromuscular monitoring. At induction, 2 mg kg−1 propofol and 1 mcg kg−1 intravenous fentanyl were applied. After the loss of eyelash reflex, 0.6 mg kg−1 intravenous rocuronium was administered. Patients were intubated at train of four (TOF) 2. Anaesthesia was continued with 50% O2 +50% air and 2% sevoflurane. Rocuronium, 0.15 mg kg−1, was administered at TOF 2 during the operation. At the end of the operation, 2 mg kg−1 sugammadex was administered. The times until TOF 0.7, 0.8 and 0.9 were recorded.

Results:

Intubation time was 132.8±46.4 s for smokers and 127.6±32.7 s for non-smokers. After sugammadex administration, the time to TOF 0.7 was 153.3±54.7 s in smokers and 125±67.2 s in non-smokers. The times were 178.4±58.8 and 146.6±72.6 s for TOF 0.8 and 200.8±55.8 s and 170.4±77.8 s for TOF 0.9 in smokers and non-smokers, respectively.

Conclusion:

Although not statistically significant, the time to reach each TOF was longer for smokers. Larger populations and different perspectives are needed to find if sugammadex use is affected by smoking, which has negative effects on the body.

Keywords:
General anaesthesia, sugammadex, smoking